期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 369, 期 2, 页码 579-583出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2008.02.066
关键词
methylene blue; leukomethylene blue; singlet oxygen; photodynamic therapy; polyacrylamide; nanoparticle platform; enzymatic reduction
资金
- NCI NIH HHS [R21CA125297, R21 CA125297-01A1, N01 CO037123, R21 CA125297, N01-CO-37123] Funding Source: Medline
- NIAID NIH HHS [N01CO37123] Funding Source: Medline
- NIEHS NIH HHS [ES08846, R01 ES008846-07, R01 ES008846, T32 ES007062] Funding Source: Medline
The ability to prevent methylene blue (MB), a photosensitizer, from being reduced by plasma reductases will greatly improve its efficacy in photodynamic therapy (PDT) applications. We have developed a delivery approach for PDT by encapsulating MB using nanoparticle platforms (NPs). The 30-nm polyacrylamide-based NPs provide protection for the embedded MB against reduction by diaphorase enzymes. Furthermore, our data shows the matrix-protected MB efficiently induces photodynamic damage to tumor cells. The unprecedented results demonstrate the significant in vitro photodynamic effectiveness of MB when encapsulated within NPs, which promises to open new opportunities for MB in its in vivo and clinical studies. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据